|
|
|
|
|
|
|
24.07.26 - 09:00
|
Banco De Sabadell SA Reveals Fall In H1 Profit (AFX)
|
|
|
ROME (dpa-AFX) - Banco de Sabadell SA (1SAB.MI) reported earnings for first half that Dropped, from last yearThe company's earnings totaled EUR971 million, or EUR0.32 per share. This compares with......
|
|
|
|
|
24.07.26 - 08:30
|
Banco Sabadell H1 Net Profit Declines (AFX)
|
|
|
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Banco Sabadell Group (1SAB.MI, SAB.MC) reported net profit of 971 million euros during the first half of 2026, down 0.5% from last year. Excluding the contribu......
|
|
|
|
|
|
|
01.07.26 - 15:12
|
ORYZON Raises €12 Million and Signs a Financing Agreement with COFIDES to Strengthen its Balance Sheet and Accelerate its Clinical Programs (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced the successful completion of a €12 million gross capital increase through the issuance of 4,444,445 new ordinary shares, at a subscription price of €2.70 per share. This pricing represents a 14.15% discount to the five-day volume-weighted average price (VWAP), which was €3.1449, and a 12.68% discount to the June 30 closing price of €3.092 per share. The offering was structured as a capital increase without the issuance of warrants. Singular Bank acted as placement agent in Spain, and All-Invest acted as placement agent in the EU and the UK. Banco Sabadell, S.A. acted as Agent Bank and Technical Pre-Financing Entity for the capital increase, while Gómez-Acebo & Pombo Abogados, S.L.P. acted as legal counsel to the Company....
|
|
|
|
|
|
|
|
|
05.05.26 - 15:30
|
Banco De Sabadell SA Profit Falls In Q1 (AFX)
|
|
|
ROME (dpa-AFX) - Banco de Sabadell SA (1SAB.MI) announced earnings for its first quarter that Dropped from the same period last yearThe company's earnings totaled EUR347 million. This compares wit......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|